Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Date:10/7/2008

jective of the study is to assess the overall tumor response rate to the combination of bavituximab with carboplatin and paclitaxel. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients enrolled in the trial are receiving up to six cycles of bavituximab in combination with carboplatin and paclitaxel. Patients may continue to receive bavituximab alone after completion of the combination regimen cycles as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of NSCLC. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... of aspirin in new super pill ORLANDO, Fla. ... (OTC Bulletin Board: CONX) announced today that its ... Indian POLYCAP Study (TIPS) to help determine patients, ... trial examined the effect of combinations of aspirin, ...
... QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today announced ... pivotal Phase 3 clinical trial of Ophena(TM) ... Phase 3 study of Ophena(TM) , the Company ... for Ophena(TM) , the most advanced estrogen-free oral ...
Cached Medicine Technology:Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 2Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 3QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3
(Date:3/1/2015)... WA (PRWEB) February 28, 2015 CrossFit Attollo ... spring they are offering a special discount to new members. ... sign up for a three month contract will receive their ... month individually would cost members $440. The three month ... per month, and then the fourth month comes in at ...
(Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
(Date:2/28/2015)... With their commitment to achieving physical results ... exercise to their already robust library of oblique exercises. ... known as, is often performed on a stationary piece ... a relatively safe manner and can be performed by ... description of “Rope Pulls” is located in the oblique ...
(Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... research is preliminary and more trials are needed, study says ... promising results from the largest clinical trial of gene therapy ... replicated and more research must be done before an effective ... but we need to make it better before we launch ...
... attack can greatly increase survival, group says , , SUNDAY, ... signs of a heart attack greatly increases the chances ... Physicians (ACEP). , "Everyone knows that a ... early signs can also include shortness of breath, unexplained ...
... Ill. A study in the Feb. 15 issue of ... a 40 minute protocol for the Maintenance of Wakefulness ... at detecting excessive daytime sleepiness (EDS) in adults who ... results also suggest that the test may not be ...
... released today at the Oncology Nursing Society (ONS) 10th ... was the strongest predictor of social disconnection in African ... Sue Heiney, PhD, RN, CS, FAAN, of the Palmetto ... the concept of social disconnection and the sociocultural influences ...
... 14 A York County jury on Friday awarded $4.4 ... brain injury at birth. The award was against Piedmont Hospital. ... assigned a nurse trainee to monitor Robin Wilson, who arrived ... The nurse misread fetal heart monitoring data showing the baby ...
... Health (TFAH) commends the U.S. Congress for supporting more ... American Reinvestment and Recovery Act of 2009. The ... and help contain the nation,s skyrocketing health care costs."Congress ... and wellness," said Jeff Levi, PhD, Executive Director of ...
Cached Medicine News:Health News:Gene Therapy Holds Promise for HIV 2Health News:Being Heart Smart Just Makes Sense 2Health News:Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable 2Health News:Study finds that using wakefulness tests to detect daytime sleepiness in drivers may be unreliable 3Health News:Social Disconnection in African American Women With Breast Cancer 2Health News:Trust for America's Health Commends Congress, Obama Administration for Historic Investment in Prevention and Wellness 2